Sökning: WFRF:(Hjalmarson Åke 1937)
> (2010-2014) >
An economic evaluat...
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.
-
Lorgelly, Paula K (författare)
-
Briggs, Andrew H (författare)
-
Wedel, Hans (författare)
-
visa fler...
-
Dunselman, Peter (författare)
-
- Hjalmarson, Åke, 1937 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
Kjekshus, John (författare)
-
- Waagstein, Finn, 1938 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
- Wikstrand, John, 1938 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
Jánosi, András (författare)
-
van Veldhuisen, Dirk J (författare)
-
Barrios, Vivencio (författare)
-
Fonseca, Cândida (författare)
-
McMurray, John J V (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-12-18
- 2010
- Engelska.
-
Ingår i: European journal of heart failure. - : Wiley. - 1879-0844 .- 1388-9842. ; 12:1, s. 66-74
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIMS: To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial. METHODS AND RESULTS: This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P < 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin ( pound1531 vs. pound1769; difference pound238; 95% CI: pound73-403, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group ( pound1769 vs. pound2072; difference pound303; 95% CI: pound138-468, P < 0.001). Overall, rosuvastatin was found to cost pound1840 (95% CI: pound562-6028) per major CV event avoided. CONCLUSION: This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
Nyckelord
- Cost-effectiveness
- Heart failure
- Statins
- Multinational trial
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lorgelly, Paula ...
-
Briggs, Andrew H
-
Wedel, Hans
-
Dunselman, Peter
-
Hjalmarson, Åke, ...
-
Kjekshus, John
-
visa fler...
-
Waagstein, Finn, ...
-
Wikstrand, John, ...
-
Jánosi, András
-
van Veldhuisen, ...
-
Barrios, Vivenci ...
-
Fonseca, Cândida
-
McMurray, John J ...
-
visa färre...
- Artiklar i publikationen
-
European journal ...
- Av lärosätet
-
Göteborgs universitet